Valoctocogene roxaparvovec-rvox (Roctavian) Coverage Criteria
Customize your policy alerts
Sign up for healthspring Policy RX501.128 alerts
Get alerted when Policy RX501.128 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity coverage for Roctavian (valoctocogene roxaparvovec-rvox), a gene therapy for adults with severe or moderately severe hemophilia A. Coverage is limited to members meeting all specified clinical, laboratory, infection, and treatment-history criteria; other indications and repeat treatment are considered unproven.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.